Story perspectives

Orca’s Tregzi Yields 94% One-Year Survival, Cuts GVHD

7/2/2026

Summary

Orca Shows Survival

Orca Therapeutics reported Tregzi achieved 94% overall survival at one year in the United States.
78% of Tregzi patients were alive without chronic GVHD at one year versus 38.4% for standard transplants.
The FDA said oral and gut membrane inflammation, diarrhea, rash and viral infections were expected side effects.
Orca set a $428,000 wholesale price, secured up to $250 million in financing, and opened a Princeton, New Jersey facility to speed delivery.

Summary

Orca Gets Approval

The FDA approved Tregzi on June 30, 2026, the first regulatory-T-cell therapy for allogeneic transplant.
FDA acting director Karim Mikhail said the therapy offers a new way to curb graft-versus-host disease.
An editorial warned future trials must compare Orca-T with post-transplant cyclophosphamide regimens.
Orca Bio’s centralized process isolates Tregs, ships fresh stem cells and frozen T cells to clinics.
Analysts say the approval could lower African patients’ dependence on expensive medical tourism.

1 of 2

Orca Shows Survival

Orca Therapeutics reported Tregzi achieved 94% overall survival at one year in the United States.
78% of Tregzi patients were alive without chronic GVHD at one year versus 38.4% for standard transplants.
The FDA said oral and gut membrane inflammation, diarrhea, rash and viral infections were expected side effects.
Orca set a $428,000 wholesale price, secured up to $250 million in financing, and opened a Princeton, New Jersey facility to speed delivery.

1 / 2